MEET DR. KHITIN, The Vein Treatment Doctor

Lev M. Khitin, M.D., F.A.C.S., a cardiovascular surgeon, originally board certified in general and cardio-thoracic surgery, is a leading varicose vein treatment specialist in NYC. He is the founder and president of the New York Vein Treatment Center, a premier medical facility dedicated to the complex evaluation and comprehensive treatment of circulatory disorders of the lower extremities. Dr. Khitin is a Fellow of American College of Surgeons and American College of Phlebology and a member of the American Society of Thoracic Surgeons, American College of Cardiology and American Medical Association, as well as of many other national and international societies. He is recognized worldwide for his achievements in the field of circulation and as a varicose vein treatment surgeon. He has pioneered the in-office management of vascular diseases with unprecedented results utilizing treatment modalities ranging from the most modern technologies of contemporary vascular medicine to the most traditional therapeutic methods.

• Cardiovascular Surgeon, President & Owner; VEIN; Manhattan NY; 2009-present
• Cardiothoracic and Endovascular Surgeon; Heart Institute; Chicago IL; 2007-2009
• Cardiac Surgeon; TCVS; Birmingham AL; 2005-2007
• Cardiothoracic Surgery; MUSC, Charleston SC; 2002-2005
• Vascular Surgery; Lahey Clinic, Burlington MA; 2000-2002
• General Surgery; Stanford-UCSF; San Francisco CA; 1995-2000

• General Surgery Board Certified: 2005
• Thoracic Surgery Board Certified: 2007
• New York State Board of Medicine: 2007
• Illinois Department of Financial and Professional Regulation: 2005
• Medical Board of Alabama: 2003
• Board of Medical Examiners, South Carolina: 2002
• Commonwealth of Massachusetts: 2000
• Medical Board of California: 1997
• American College of Phlebology: 2007
• Society of Thoracic Surgeons: 2002
• American College of Surgeons: 2000
• American College of Cardiology: 2002
• Southern Medical Association: 2002
• American Medical Association: 1995

Ethical process in human research published in thoracic surgery journals; M. Block, L. Khitin, R. Sade. Annals of Thoracic Surgery, 2006; 82: 6-12

Prevention of thrombosis and embolism in children with mechanical valve prostheses: warfarin vs. antiplatelet agents; L. Khitin, R. Sade, S. Bradley, F.A. Crawford Jr., C. Widener. The Journal of Heart Valve Disease, 2006 May; 15(3): 394-9

Hypophosphatemia and global neurological deficit after cardiopulmonary bypass; L. Khitin, K. Kim, J.S. Ikonomidis, M. Stroud, A.J. Crumbley, F.A. Crawford Jr. Journal of Cardiothoracic and Vascular Anesthesia, 2005

Systemic temperature and paralysis after thoracoabdominal and descending aortic operations; L. Svensson, L. Khitin, E. Nadolny, W. Kimmel. Archives of Surgery, 2003 Feb; 138(2): 175-9

Aortic cross-sectional area to height ratio timing of aortic surgery in asymptomatic patients with Marfan’ syndrome; L. Svensson, L. Khitin. The Journal of Thoracic and Cardiovascular Surgery, 2002 Feb; 123(2): 360-1

Mast cell tryptase regulates colonic myocytes through proteinase-activated receptor-2; C. Corvera, O. Dery, K. McConalogue, L. Khitin, S. Bohm, W. Kong, W. Raymond, G. Caughey, N. Bunnett. Journal of Clinical Investigation, 1997 Sept, 100 (6): 1383-93

Luminal trypsin may regulate enterocytes through proteinase-activated receptor-2; W. Kong, K. McConalogue, L. Khitin, M. Hollenberg, D. Payan, S. Bohm, N. Bunnett. Proceedings of Natural Academy of Sciences, USA, 1997 Aug, 94: 8884-9

Identification of potential tyrosine-containing endocytic motifs in the carboxyl-tail and seven transmembrane domain of the neurokinin 1 receptor; S. Bohm, L. Khitin, S. Smeekens, E. Grady, D. Payan, N. Bunnett. Journal of Biological Chemistry, 1997 Jan, 272: 2363-72

Mechanism of desensitization and resensitization of proteinase-activated receptor-2; S. Bohm, L. Khitin, E. Grady, G. Aponte, D. Payan, N. Bunnett. Journal of Biological Chemistry, 1996 Sep, 271 (36): 22003-16

Photocolorimetric method for evaluation dynamics of blood flow; L. Khitin, L. Zelichenko, G. Poriadin. Pathologic Physiology and Experimental Therapy, 1994 Jul-Sep (3): 55-7

Restitution of population of mesenteric mast cells.; L. Khitin, L. Zelichenko, G. Poriadin. Bulletin of Experimental Biology and Medicine, 1993 Dec, 116 (12): 558-91

Method of in vivo study of microcirculation in mesentery; L. Khitin, L. Zelichenko, G. Poriadin. Pathologic Physiology and Experimental Therapy, 1993 Jul-Dec, (4): 62

Effect of Mildronate on secretory activity of the mesentery mast cells; L. Khitin, G. Poriadin, L. Zelichenko Allergology and Immunology, 1992 Febr: 102-5

Quantitative evaluation of mast cells degranulation; L. Khitin, G. Poriadin, L. Zelichenko Immunology, 1991 March: 59-61

Surgery for reflux esophagitis; L. Khitin, D. Brams. Internist’s Illustrated Guide to Gastrointestinal Surgery; E. Wu, K. Aziz. Humana Press, 2002

Hiatal hernia and paraesophageal hernia repair; L. Khitin, D. Brams. Internist’s Illustrated Guide to Gastrointestinal Surgery; E. Wu, K. Aziz. Humana Press, 2002

Surgical management of achalasia; J. Braveman, L. Khitin, D. Brams. Internist’s Illustrated Guide to Gastrointestinal Surgery; E. Wu, K. Aziz. Humana Press, 2002

Gastric Cancer: important factors for general surgeon; K. Barwick, L. Khitin, K. Kirkwood. Surgical Oncology Clinics of North America, W. B. Saunders, Philadelphia, 1996, 6 (3): 495-514

Carcinosarcoma of the mediastinum: a previously unreported entity; B. Johnston, L. Khitin, R. Gitter, B. Allen. Journal of Thoracic Medicine (in print)

An aneurysm of right-sided aortic arch with mirror-image brachiocephalic branching; L. Khitin, K. Kim, K. Phillips, J. Ikonomidis. Journal of Thoracic Imaging, 2005 Nov; 20(4): 307-9

Transxyphoid approach to retrieval of retained pacemaker leads using laser sheath; L. Khitin, K. Kim, J. Kratz. Pacing and Clinical Electrophysiology, 2004 Feb; 28(2): 157-8

Cancer in the gastric remnant after gastric bypass; L. Khitin, R. Roses, D. Birkett. Current Surgery, 2003 Sept-Oct, 60(5): 521-3

Inventions and Investigations

• Balloon occlusion device for proximal vascular anastomosis during coronary artery or other vascular surgery; L. Khitin, J. Kratz. Patented invention PCT/US2005/013471:60/563,664, Charleston SC, March 2004
• Method for quantitative evaluation of mast cells degranulation; L. Khitin, G. Poriadin, L. Zelichenko. Patented invention 1774219, Moscow, July 1992
• Integrium, Principal Investigator. Protocol CDx000004: Identification of gene expression patterns in circulating cells that predict the presence of coronary artery disease; completed Dec. 2008
• Pfizer, Principal Investigator. Protocol A6141079: The effect of Eplerenone versus placebo on cardiovascular mortality and heart failure hospitalization in subjects with NYHA class II chronic systolic heart failure (EMPHASIS-HF); completed Dec. 2008
• Pfizer, Principal Investigator. Protocol A1481244: A Multinational, Multicenter, Randomized, Parallel Group, Double-Blind Study to Assess The Efficacy and Safety of 1MG, 5MG and 20 MG TID of Oral Sildenafil in the Treatment of Subjects Aged 18 Years and Over with Pulmonary Arterial Hypertension (PAH); completed Dec. 2008
• Eisai Global Clinical Development, Principal Investigator. Protocol E5555-G000-202: A randomized, double-blind, placebo-controlled study of the safety and tolerability of E5555, and its effects on clinical events and biomarkers in patients with non-ST-segment elevation acute coronary syndrome (in progress)
• Kendle, Principal Investigator. Protocol DAR-311: DORADO: A phase III, randomized, double-blind, placebo-controlled, multi-center, parallel group study to evaluate the efficacy and safety of fixed doses of Darusentan in subjects with resistant systolic hypertension receiving combination therapy with four or more antihypertensive drugs, including a diuretic (in progress)
• Kendle, Principal Investigator. Protocol DAR-311-E: DORADO-EX: A dose blinded, long-term safety extension study to the phase 3 DORADO study of Darusentan in resistant hypertension (in progress)
• RegeneRx, Principal-Investigator. Protocol SSPU: A randomized, double-blind, placebo-controlled, dose-response study of the safety and efficacy of Thymosin Beta 4 in the treatment of patients with pressure ulcers; completed Dec. 2008
• Allon, Principal Investigator. Protocol AL-208-201: A phase II study designed to evaluate the safety, tolerability, and effect of intravenous AL-208, followed by a placebo-controlled evaluation of a single dose of AL-208, on mild cognitive impairment following coronary artery bypass graft surgery; completed Dec. 2007
• Angiotech, Principal Investigator. Protocol 011-ACVC05: A controlled, randomized, single-blind, milti-center pivotal clinical study using Angiotech CVC to prevent bacterial colonization on short term central venous catheters; completed Jul. 2007
• Medicure International Inc., Principal Investigator. Protocol NCT00402506: Safety and efficacy study to confirm the cardioprotective effects of MC-1 in patients undergoing high-risk CABG; completed Nov. 2007
• Cadence Pharmaceuticals, Inc., Principal Investigator. Protocol CPI-226-03: A Phase 3, Multicenter, Randomized, Evaluation Committee-Blinded Study to Assess the Efficacy of Topical Administration of Omiganan 1.0% Gel in Preventing Local Catheter Site Infections and Catheter Colonization in Patients Undergoing Central Venous Catheterization; completed Nov. 2007
• Sanofi Aventis, Co-Investigator. Protocol 65815/71869-EFC 6034: An international, multicenter, randomized, double-blind, double-dummy, parallel group, study of 3 or 6-month treatment with SSR126517E versus warfarin in patients with PE with or without DVT; completed Dec. 2006
• Angiotech, Co-Investigator. Protocol 011-ACVC05: A controlled, randomized, single-blind, milti-center pivotal clinical study using Angiotech CVC to prevent bacterial colonization on short term central venous catheters; completed Jul. 2007
• The Medicines Company, Co-Investigator. Protocol TMC-CLV-03-05: A randomized, open label, prospective, parallel group comparison of Clevelox™ versus nicardipine for the treatment of hypertension as clinically required postoperatively until discharge from the intensive care unit; completed Oct. 2006
• Avant Immunotherapeutics Inc., Co-Investigator. Protocol TP10-ACS-002: Phase II randomized, double-controlled study of the safety and efficacy of human recombinant soluble complement receptor type 1 in adults
• Prevention of thrombosis and embolism in children with mechanical valve prostheses: warfarin vs. antiplatelet agents; L. Khitin, R. Sade, S. Bradley, F.A. Crawford Jr., C. Widener. Society for Heart Valve Disease, 3^rd Biennial Meeting of the Society for Heart Valve Disease, 2005, Vancouver, British Columbia
• Ethical process in publication of human research; M. Block, L. Khitin, R. Sade. Southern Thoracic Surgical Association, 52^nd Annual Meeting, 2005, Orlando, FL
• Influence of systemic temperature on transient, delayed, and permanent paralysis after complex thoracoabdominal and descending thoracic aortic operations; L. Svensson, L. Khitin, E. Nadolny, W. Kimmel. The American Association for Thoracic Surgery, 82^nd Annual Meeting, 2002, Washington DC
• Cleavage and activation of proteinase-activated receptor-2 by trypsin, factor Xa, mast cell tryptase and chymotrypsin; L. Khitin, C. Corvera, S. Bohm, S. Kong, G. Caughey, D. Payan, N. Bunnett. 11^th Annual Research Day, UCSF, 1998, San Francisco, CA
• Cleavage and activation of proteinase-activated receptor-2 by trypsin, factor Xa, mast cell tryptase and chymotrypsin; S. Bohm, C. Corvera, L. Khitin, N. Bunnett.  FEBS, Special Meeting, 1997, Amsterdam, Netherlands
• Mast cell tryptase regulates colonic myocytes through proteinase-activated receptor-2; C. Corvera, O. Dery, K. McConalogue, L. Khitin, S. Bohm, W. Kong, G. Raymond, G. Caughey, N. Bunnett.  Gastroenterology.  Digestive Disease Week, 1997, Washington, DC
• Proteinase-activated receptor-2 (PAR-2) regulates prostaglandin secretion and CCK release from intestinal epithelial cells; W. Kong, L. Khitin, R. Liddle, S. Coughlin, D. Payan, K. Kirkwood, N. Bunnett, S. Bohm.  Gastroenterology, 110(4): A1060 Digestive Disease Week, 1996, San Francisco, DC
• Novel mechanism of desensitization of protease-activated receptor-2 (PAR-2); S. Bohm, L. Khitin, E. Grady, P. Gamp, M. Lovett, D. Payan, N. Bunnett.  Gastroenterology, 110(4): A1089, Digestive Disease Week, 1996, San Francisco, CA

Varicose and Spider Veins: The Cure and Consequences of Misdiagnosis: http://www.theepochtimes.com/n3/1066359-varicose-and-spider-veins-the-cure-and-consequences-of-misdiagnosis/

Circulation: Myths and Realities http://www.theepochtimes.com/n3/1324306-circulation-myths-and-realities/

Subtle Signs of Vein Disease People Don’t Recognize: http://www.theepochtimes.com/n3/1741803-subtle-signs-of-vein-disease-people-dont-recognize/